Last reviewed · How we verify
Oxytocin 5 Usp Units In Dextrose 5% (OXYTOCIN)
Oxytocin 5 Usp Units In Dextrose 5% is a medication developed by Novartis and currently owned by Fresenius Kabi USA. It is a small molecule that targets the oxytocin receptor, classified as an oxytocic drug. Oxytocin 5 Usp Units In Dextrose 5% is FDA-approved for incomplete miscarriage, induction of labor, postpartum hemorrhage, and pregnancy with abortive outcome. The medication is off-patent, with three generic manufacturers available. Key safety considerations include careful dosing and monitoring due to potential risks of uterine rupture and other complications.
At a glance
| Generic name | OXYTOCIN |
|---|---|
| Sponsor | Fresenius Kabi |
| Drug class | Adrenocorticotropic Hormone [EPC] |
| Target | Oxytocin receptor |
| Modality | Recombinant protein |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1980 |
Approved indications
- Incomplete miscarriage
- Induction of labor
- Postpartum hemorrhage
- Pregnancy with abortive outcome
Common side effects
Key clinical trials
- Efficacy of Intravenous Oxytocin to Speed Recovery After THA (PHASE2)
- Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain (PHASE2)
- Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage (PHASE4)
- 3-hour Versus 12-hour Double-balloon Catheter for Labor Induction: a Randomized Trial (NA)
- The Stimulation To Induce Mothers Study (PHASE4)
- Improving Safe Vaginal Deliveries for Delivering Mothers by Implementing an Intervention Package of 11 Evidence-based Practices and Robson Classification at a Semi-urban Hospital in Dhaka, Bangladesh (NA)
- Oxytocin to Treat PTSD (PHASE2)
- EVALUATİON OF THE EFFECTİVENESS OF A MODEL-BASED HYPNOBREASTFEEDİNG EDUCATİON PROGRAM GİVEN TO PRİMİPAROUS PREGNANT WOMEN (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxytocin 5 Usp Units In Dextrose 5% CI brief — competitive landscape report
- Oxytocin 5 Usp Units In Dextrose 5% updates RSS · CI watch RSS
- Fresenius Kabi portfolio CI